RGNX vs. RLAY, CRGX, KYTX, CGEM, MESO, IMTX, BCRX, CABA, HLVX, and NVAX
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Relay Therapeutics (RLAY), CARGO Therapeutics (CRGX), Kyverna Therapeutics (KYTX), Cullinan Oncology (CGEM), Mesoblast (MESO), Immatics (IMTX), BioCryst Pharmaceuticals (BCRX), Cabaletta Bio (CABA), HilleVax (HLVX), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO (NASDAQ:RGNX) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
REGENXBIO currently has a consensus price target of $38.45, suggesting a potential upside of 143.85%. Relay Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 338.45%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than REGENXBIO.
In the previous week, REGENXBIO had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 5 mentions for REGENXBIO and 2 mentions for Relay Therapeutics. REGENXBIO's average media sentiment score of 0.59 beat Relay Therapeutics' score of -0.81 indicating that REGENXBIO is being referred to more favorably in the media.
REGENXBIO received 387 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 65.89% of users gave REGENXBIO an outperform vote while only 59.02% of users gave Relay Therapeutics an outperform vote.
REGENXBIO has a net margin of -291.99% compared to Relay Therapeutics' net margin of -1,263.49%. Relay Therapeutics' return on equity of -42.43% beat REGENXBIO's return on equity.
REGENXBIO has higher revenue and earnings than Relay Therapeutics. REGENXBIO is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
REGENXBIO has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 13.1% of REGENXBIO shares are held by insiders. Comparatively, 3.5% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
REGENXBIO and Relay Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
